Every material Form 8-K CRISPR Therapeutics AG has filed with the SEC since August 03, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CRISPR Therapeutics reported third quarter 2026 results, with total revenue of $12.7 million versus $0.9 million a year earlier and a net loss of $111.4 million versus $106.4 million. The company said CASGEVY revenue reached $99 million, and cash and marketable securities totaled $2,276.6 million at September 30, 2026, which shareholders may weigh against the continued losses.
Total revenue was $12.7 million for Q3 2026, compared with $0.9 million for Q3 2025.
Net loss was $111.4 million, or $1.15 per share, versus a net loss of $106.4 million, or $1.17 per share, a year earlier.
CASGEVY revenue was $99 million in Q3 2026, up 30% quarter-over-quarter.
Cash, cash equivalents, and marketable securities were $2,276.6 million as of September 30, 2026.
CRISPR Therapeutics promoted Andrew J. Silver, its SVP of Finance, to Chief Financial Officer effective immediately on October 19, 2026. CFO Raju Prasad resigned the same day to pursue external opportunities and is expected to remain employed until on or before November 30, 2026. The filing says Dr. Prasad's resignation was not due to any disagreement with the company on financial or accounting matters.
Andrew J. Silver, 42, becomes CFO and principal financial and accounting officer effective October 19, 2026; he has been SVP, Finance since January 2025 and joined the company in October 2018.
Silver's employment agreement sets an annual salary of $515,000, a target bonus of 45% of base salary, and a one-time grant of 25,000 restricted stock units vesting on the second anniversary of the grant date.
Raju Prasad, Ph.D. resigned as CFO; he is expected to remain employed until a date on or before November 30, 2026.
Under the agreement, termination without Cause or resignation for Good Reason carries a six-month notice period, extended to 12 months if it occurs within 12 months after a Change in Control.
CRISPR Therapeutics reported second quarter 2026 results, with total revenue of $10.2 million versus $0.9 million a year earlier and a net loss of $91.2 million, down from $208.5 million. The company stated CASGEVY generated $76 million in second quarter revenue and that the FDA approved CASGEVY for children 2 years and older, while cash and marketable securities totaled $2.36 billion at June 30, 2026.
Net loss was $91.2 million, or $0.94 per share, versus a net loss of $208.5 million, or $2.40 per share, in Q2 2025
Total revenue was $10.2 million versus $0.9 million a year earlier; the filing shows $10.0 million of collaboration revenue
Cash, cash equivalents and marketable securities were $2,364.4 million at June 30, 2026, including $585.4 million of net proceeds from convertible senior notes issued in March 2026
Acquired in-process R&D expense fell to $2.5 million from $96.3 million, which the company linked to the 2025 Sirius Agreement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CRISPR Therapeutics AG filing is on SEC EDGAR ↗. 8-K briefs of other companies →